Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Petar Svorcan"'
Autor:
David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 694 (2024)
This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting Mycobacterium avium subspecies paratuberculosis (MAP), long considered a putative cause, would favorably affect Cro
Externí odkaz:
https://doaj.org/article/e2493f4da86e452f9ac5eb4e6ef7ff2d
Autor:
Petar Svorcan, Maja Stojanović, Predrag Stevanović, Aleksandar Karamarković, Radmilo Janković, Nebojša Ladjević
Publikováno v:
Acta Clinica Croatica, Vol 55., Iss 2., Pp 316-321 (2016)
The purpose of the study was to point to the importance of measuring intra-abdominal pressure (IAP) and of early recognition of the consequences of increased IAP on basic vital functions. Measurement of IAP via urinary bladder was conducted every 12
Externí odkaz:
https://doaj.org/article/848f2872e95f4c69b3d0c35938ce4cca
Autor:
Sanja Z Despotović, Novica M Milićević, Dragoslav P Milošević, Nebojša Despotović, Predrag Erceg, Petar Svorcan, Udo Schumacher, Sebastian Ullrich, Gordana Mihajlović, Dragan Kalem, Srđan Marković, Ivana M Lalić, Aleksandar J Krmpot, Mihailo D Rabasović, Dejan V Pantelić, Svetlana Z Jovanić, Thomas Rösch, Živana Milićević
Publikováno v:
Tumor Biology, Vol 39 (2017)
In recent years, it has been demonstrated that malignancy arises and advances through the molecular interplay between tumor cells and non-malignant elements of the tumor stroma, that is, fibroblasts and extracellular matrix. However, in contrast to t
Externí odkaz:
https://doaj.org/article/7ea0a0e1efc34154b74f0399d55f0588
Autor:
Miloš Mitrović, Verica Stanković-Popović, Maja Tolinački, Nataša Golić, Svetlana Soković Bajić, Katarina Veljović, Branislav Nastasijević, Ivan Soldatović, Petar Svorcan, Nada Dimković
Publikováno v:
Journal of Renal Nutrition
ObjectiveAltering dysbiotic gut flora through synbiotic supplementation has recently been recognized as a potential treatment strategy to reduce the levels of gut-derived uremic toxins and decrease inflammation. Assessing its efficacy and safety has
Autor:
Branimir Zogovic, Srdjan Markovic, Nikola Panic, Marijana Jankovic, Tamara Knezevic Ivanovski, Petar Svorcan, Dino Tarabar, Ana Kalaba
Publikováno v:
Acta Scientific Gastrointestinal Disorders. 4:27-34
Publikováno v:
Acta Scientific Gastrointestinal Disorders. 4:19-26
Autor:
Maja Ruzic, Petar Svorcan, Zeljko Mijailovic, Tatjana Cvejic Pasic, Ksenija Bojovic, Milena Petrovic, Ivana Milosevic, Jelena Jordovic, Maja Jovanovic, Jasmina Simonovic-Babic
Publikováno v:
The Journal of Infection in Developing Countries. 14:117-124
Background: Serbia has an intermediate estimated prevalence of chronic hepatitis C (CHC) infection, approximately 1.13%, with hepatitis C remaining one of the leading causes of liver-related morbidity and mortality in Serbia with impaired quality of
Autor:
Aleksandar Jovanović, Goran Knezevic, Petar Svorcan, Lela Trikos, Njegica Jojic, Marko Zivanovic
Publikováno v:
Vojnosanitetski Pregled, Vol 76, Iss 12, Pp 1217-1226 (2019)
Background/Aim. Inflammatory bowel diseases (IBD), which include the ulcerative colitis (UC) and the Crohn?s disease (CD), are chronic diseases, the course of which is under the influence of numerous psychosocial factors. The aim of this study was th
Autor:
Petar Svorcan, Zeljko Mijailovic, Darko Nozic, Ranko Škrbić, Jasmina Simonovic-Babic, Tatjana Cvejic, P Milos Stojiljkovic, Ksenija Bojovic, Maja Jovanovic, Milotka Fabri
Publikováno v:
Vojnosanitetski Pregled, Vol 76, Iss 5, Pp 531-536 (2019)
Background/Aim. The era of direct-acting antiviral (DAA) regimen in the treatment of chronic hepatitis C virus (HCV) started in 2011. The aim of this study was to assess the antiviral efficacy and safety of DAA regimen, ombitasvir (OBV)/paritaprevir
Autor:
Mirjana Cvetkovic, Srdjan Markovic, Petar Svorcan, Branimir Zogovic, Tamara Knezevic Ivanovski
Publikováno v:
Inflammatory Bowel Diseases